Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Malaria Journal
Published in: Malaria Journal 1/2011

Open Access 01-12-2011 | Research

Icacina senegalensis (Icacinaceae), traditionally used for the treatment of malaria, inhibits in vitro Plasmodium falciparum growth without host cell toxicity

Authors: Serigne O Sarr, Sylvie Perrotey, Ibrahima Fall, Saïd Ennahar, Minjie Zhao, Yérim M Diop, Ermanno Candolfi, Eric Marchioni

Published in: Malaria Journal | Issue 1/2011

Login to get access

Abstract

Background

With the aim of discovering new natural active extracts against malaria parasites, Icacina senegalensis was selected after an ethnopharmacological survey conducted on plants used in traditional malaria treatment in Senegal.

Methods

Different concentrations of the plant extract and fractions were tested on synchronized Plasmodium falciparum cultures at the ring stage using the parasite lactate dehydrogenase assay. Their haemolytic activity and in vitro cytoxicity were evaluated. The chromatographic profiles of active fractions were also established.

Results

The plant extract and fractions revealed anti-plasmodial activity (IC50 < 5 μg/mL) with no toxicity (Selectivity indexes >10). The dichloromethane fraction showed stronger anti-plasmodial activity than the total extract.

Conclusion

Anti-plasmodial activity and toxicity of I. senegalensis are reported for the first time and showed promising results in malaria field research.
Appendix
Available only for authorised users
Literature
1.
2.
Trape JF, Pison G, Spiegel A, Enel C, Rogier C: Combating malaria in Africa. Trends Parasitol. 2002, 18: 224-230. 10.1016/S1471-4922(02)02249-3.CrossRefPubMed
3.
Benoît-Vical F: Ethnomedicine in malaria treatment. Idrugs. 2005, 8: 45-52.PubMed
4.
Sarr SO, Ciss M, Fall D, Diedhiou A, Diop YM, Diop A, Smine A, Ndiaye B: Contrôle de la qualité d'une combinaison libre d'amodiaquine et d'artésunate. Ann Fals Exp Chim. 2008, 968: 40-45.
5.
Willcox ML, Bodeker G: Plant-based malaria control: research initiative on traditional antimalarial methods. Parasitol Today. 2000, 16: 220-221. 10.1016/S0169-4758(00)01678-1.CrossRefPubMed
6.
Harvey AL: Natural products in drug discovery. Drug Discov Today. 2008, 13: 894-901. 10.1016/j.drudis.2008.07.004.CrossRefPubMed
7.
Kirkpatrick P: Stritching together naturally. Nature. 2002, 1: 748-10.1038/nrd921.
8.
Chotivanich K, Sattabongkot J, Choi YK, Park JS, Sritabal J, Lim CS, Udomsangpetch R, White NJ, Lee WJ: Antimalarial drug susceptibility of Plasmodium vivax in the Republic of Korea. Am J Trop Med Hyg. 2009, 80 (Suppl 6): 902-904.PubMedCentralPubMed
9.
Kaddouri H, Nakache S, Houzé S, Mentré F, Le Bras J: Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from Africa using Plasmodium lactate dehydrogenase immunodetection assay and inhibitory Emax model for precise IC50 measurement. Antimicrob Agents Chemother. 2006, 50: 3343-3349. 10.1128/AAC.00367-06.PubMedCentralCrossRefPubMed
10.
Tritten L, Matile H, Brun R, Wittlin S: A new double-antibody sandwich ELISA targeting Plasmodium falciparum aldolase to evaluate anti-malarial drug sensitivity. Malar J. 2009, 8: 226-10.1186/1475-2875-8-226.PubMedCentralCrossRefPubMed
11.
Akaddar A, Doderer-Lang C, Marzahn MR, Mousli M, Helle K, Van Dorsselaer A, Aunis D, Dunn BM, Metz-Boutigue MH, Candolfi E: Catestatin, an endogenous Chromogranin A-derived peptide, inhibits in vitro growth of Plasmodium falciparum. Cell Mol Life Sci. 2010, 67 (Suppl 6): 1005-1015. 10.1007/s00018-009-0235-8.PubMedCentralCrossRefPubMed
12.
Trager W, Jensen J: Human malaria parasites in continuous culture. Science. 1976, 193: 673-675. 10.1126/science.781840.CrossRefPubMed
13.
El Tahir A, Satti MHG, Khalid SA: Antiplasmodial activity of selected Sudanese medicinal plants with emphasis on Maytenus senegalensis (Lam.) Exell. J Ethnopharmacol. 1999, 64: 227-233. 10.1016/S0378-8741(98)00129-9.CrossRefPubMed
14.
Karou D, Dicko M, Sanon S, Simpore J, Traoré AS: Antimalarial activity of Sida acuta Burm. f. (Malvaceae) and Pterocarpus erinaceus Poir. (Fabaceae). J Ethnopharmacol. 2003, 89 (Suppl 2-3): 291-294. 10.1016/j.jep.2003.09.010.CrossRefPubMed
15.
Lelièvre J, Berry A, Benoît-Vical F: An alternative method for Plasmodium culture synchronization. Exp Parasitol. 2005, 109: 195-197.CrossRefPubMed
16.
Wiehart UI, Rautenbach M, Hoppe HC: Selective lysis of erythroytes infected with the trophozoite stage of Plasmodium falciparum by polyene macrolide antibiotics. Biochem Pharmacol. 2006, 71 (Suppl 6): 779-90. 10.1016/j.bcp.2005.12.012.CrossRefPubMed
17.
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth. 1983, 65: 65-63. 10.1016/0022-1759(83)90303-4.CrossRef
18.
Horii I, Yamada H: In vitro hepatotoxicty testing in the early phase of drug discovery. AATEX. 2007, 14: 437-447.
19.
Doderer C, Heschung A, Guntz P, Cazenave JP, Hansmann Y, Senegas A, Pfaff AW, Abdelrahman T, Candolfi E: A new ELISA kit which uses a combination of Plasmodium falciparum extract and recombinant Plasmodium vivax antigens as an alternative to IFAT for detection of malaria antibodies. Malar J. 2007, 6: 19-10.1186/1475-2875-6-19.PubMedCentralCrossRefPubMed
20.
Neuwinger HD: African Ethnobotany: Poisons and Drugs: Chemistry, Pharmacology, Toxicology. 1996, Weinheim: Chapman & Hall, 541-544.
21.
N'diaye M, Diatta W, Sy GY, Fall AD, Faye B, Bassène E: Activité antihyperglycémiante de l'extrait éthanolique de feuilles d'Icacina senegalensis Juss (Icacinaceae). Med Afr Noire. 2008, 5509: 441-445.
22.
Vanhaelen M, Plancho C, Vanhaelen-Fastre R, On'okoko P: Terpenic constituents from Icacina senegalensis. J Natural Producta. 1987, 50 (Suppl 2): 312-10.1021/np50050a048.CrossRef
23.
Soicke H, Görler K, Waring H: Terpenic constituents from Icacina senegalensis. Planta Med. 1991, 57 (Suppl 1): 86-87. 10.1055/s-2006-960030.CrossRefPubMed
24.
Weniger B, Robledo S, Arango GJ, Deharo E, Aragon R, Muñoz V, Callapa J, Lobstein A, Anton R: Antiprotozoal activities of Colombian plants. J Ethnopharmacol. 2001, 78: 193-200. 10.1016/S0378-8741(01)00346-4.CrossRefPubMed
25.
Soh PN, Benoît-Vical F: Are West African plants a source of future antimalarial drugs?. J Ethnopharmacol. 2007, 114: 130-140. 10.1016/j.jep.2007.08.012.CrossRefPubMed
26.
Ramazani A, Zakeri S, Sardari S, Nastaran K, Djadidt ND: In vitro and in vivo antimalarial activity of Boerhavia elegans and Solanum surattense. Malar J. 2010, 9: 124-10.1186/1475-2875-9-124.PubMedCentralCrossRefPubMed
27.
Cos P, Vlietinck AJ, Berghe DV, Maes L: Antiinfective potential of natural products: How to develop a stronger in vitro 'proof-of-concept'. J Ethnopharmacol. 2006, 106: 290-302. 10.1016/j.jep.2006.04.003.CrossRefPubMed
28.
Houghton PJ, Howes MJ, Lee CC, Steventon G: Uses and abuses of in vitro tests in ethnopharmacology:Visualizing an elephant. J Ethnopharmacol. 2007, 110: 391-400. 10.1016/j.jep.2007.01.032.CrossRefPubMed
29.
De Monbrison F, Maitrejean M, Latour C, Bugnazet F, Peyron F, Barron D, Picot S: In vitro antimalarial activity and 8-(1;1)-DMA-kaempferide. Acta Trop. 2006, 97: 102-107. 10.1016/j.actatropica.2005.09.004.CrossRefPubMed
30.
Tasdemir D, Lack G, Brun R, Rüedi P, Scapozza L, Perozzo R: Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem. 2006, 49 (Suppl 11): 3345-3353. 10.1021/jm0600545.CrossRefPubMed
31.
Benoît-Vical F, Imbert C, Bonfils J-P, Sauvaire Y: Antiplasmodial and antifungal activities of iridal, a plant triterpenoid. Phytochemistry. 2003, 62 (Suppl 5): 747-751.CrossRefPubMed
32.
Pink R, Hudson A, Mouries MA, Bending M: Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005, 4: 727-740. 10.1038/nrd1824.CrossRefPubMed
33.
Jonville MC, Kodja H, Humeau L, Fourne J, De Mol P, Cao M, Angenot L, Frederich M: Screening of medicinal plants from Reunion Island for antimalarial and cytotoxic activity. J Ethnopharmacol. 2008, 120: 382-386. 10.1016/j.jep.2008.09.005.CrossRefPubMed
34.
Lusakibanza M, Mesia G, Tona G, Karemere S, Lukuka A, Tits M, Angenot L, Frederich M: In vitro and in vivo antimalarial and cytotoxic activity of five plants used in Congolese traditional medicine. J Ethnopharmacol. 2010, 129: 398-402. 10.1016/j.jep.2010.04.007.CrossRefPubMed
35.
Benoit-Vical F, Valentin A, Cournac V, Pélissier Y, Mallié M, Bastide JM: In vitro antiplasmodial activity of stem and root extracts of Nauclea latifolia S.M. (Rubiaceae). J Ethnopharmacol. 1998, 61: 173-178. 10.1016/S0378-8741(98)00036-1.CrossRefPubMed
36.
Phillipson JD, Wright CW: Can ethnopharmacology contribute to the development of antimalarial agents?. J Ethnopharmacol. 1991, 32: 155-165. 10.1016/0378-8741(91)90113-R.CrossRefPubMed
37.
Benoît-Vical F, Valentin A, Pélissier Y, Diafouka F, Marion C, Koné-Bamba D, Mallié M, Bastide JM: Antimalarial activity in vitro of vegetal extracts used in West African traditional medicine. Am J Trop Med Hyg. 1996, 54: 67-71.
Metadata
Title
Icacina senegalensis (Icacinaceae), traditionally used for the treatment of malaria, inhibits in vitro Plasmodium falciparum growth without host cell toxicity
Authors
Serigne O Sarr
Sylvie Perrotey
Ibrahima Fall
Saïd Ennahar
Minjie Zhao
Yérim M Diop
Ermanno Candolfi
Eric Marchioni
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2011
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-10-85

Other articles of this Issue 1/2011

Malaria Journal 1/2011 Go to the issue

Research

Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-type PfATPase6 though sensitive to artesunate in vitro

Research

Genetic and phenotypic variation of the malaria vector Anopheles atroparvus in southern Europe

Research

Changes in health workers' malaria diagnosis and treatment practices in Kenya

Research

Suppression of circulating IgD+CD27+ memory B cells in infants living in a malaria-endemic region of Kenya

Research

Malaria elimination in Isabel Province, Solomon Islands: establishing a surveillance-response system to prevent introduction and reintroduction of malaria

Research

Immunization with different Pf AMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits